Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1029-1036

  Holtan, Shernan G ^a   Verneris, Michael R ^a   Schultz, Kirk R ^b,c   Newell, Laura F ^d   Meyers, Gabrielle ^d   He, Fiona ^e   DeFor, Todd E ^a   Vercellotti, Gregory M ^a   Slungaard, Arne ^a   MacMillan, Margaret L ^a   Cooley, Sarah A ^a   Blazar, Bruce R ^a   Panoskaltsis Mortari, Angela ^a   Weisdorf, Daniel J ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Blood and Marrow Transplant Clinical Trials Network   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic cell transplantation; Angiogenic factor; Epidermal growth factor; Follistatin; Placental growth factor; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; CORTICOSTEROID; ENDOGLIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FOLLISTATIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LEPTIN; MYCOPHENOLATE MOFETIL; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; DONOR; HEMATOPOIETIC CELL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TREATMENT RESPONSE; ACUTE DISEASE; ALLOTRANSPLANTATION; BLOOD; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANGIOPOIETIN-2; ANTIGENS, CD; BIOMARKERS; BONE MARROW TRANSPLANTATION; CHILD; ENDOGLIN; EPIDERMAL GROWTH FACTOR; FEMALE; FOLLISTATIN; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947494554     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.02.018     Document Type: Article

References (46)

1. Holtan S.G., Pasquini M., Weisdorf D.J. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014, 124:363-373.
2. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
3. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005, 106:1495-1500.
4. Brent L., Medawar P. Quantitative studies on tissue transplantation immunity. VII. The normal lymphocyte transfer reaction. Proc R Soc Lond B Sci 1966, 165:281-307.
5. Penack O., Henke E., Suh D., et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst 2010, 102:894-908.
6. Leonhardt F., Grundmann S., Behe M., et al. Inflammatory neovascularization during graft-versus-host disease is regulated by alphav integrin and miR-100. Blood 2013, 121:3307-3318.
7. Hase S., Nakazawa S., Tsukamoto Y., Segawa K. Effects of prednisolone and human epidermal growth factor on angiogenesis in granulation tissue of gastric ulcer induced by acetic acid. Digestion 1989, 42:135-142.
8. Ravindranath N., Wion D., Brachet P., Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001, 22:432-443.
9. Oikonomou K.A., Kapsoritakis A.N., Kapsoritaki A.I., et al. Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage?. Growth Factors 2010, 28:461-466.
10. Sinha A., Nightingale J., West K.P., et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350-357.
11. Kim D.H., Lee N.Y., Lee M.H., Sohn S.K. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:1408-1416.
12. Li J.Y., Su C.H., Wu Y.J., et al. Therapeutic angiogenesis of human early endothelial progenitor cells is enhanced by thrombomodulin. Arterioscler Thromb Vasc Biol 2011, 31:2518-2525.
13. Rachakonda S.P., Penack O., Dietrich S., et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol 2014, 32:3421-3427.
14. Min C.K., Kim S.Y., Lee M.J., et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 38:149-156.
15. Nachbaur D., Schumacher P., Auberger J., et al. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:942-947.
16. Lunn R.A., Sumar N., Bansal A.S., Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology 2005, 10:107-114.
17. Porkholm M., Bono P., Saarinen-Pihkala U.M., Kivivuori S.M. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant 2013, 48:50-55.
18. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002, 99:11205-11210.
19. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118:1685-1692.
20. Tichelli A., Gratwohl A. Vascular endothelium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:139-148.
21. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
22. Bolanos-Meade J., Logan B.R., Alousi A.M., et al. Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802. Blood 2014, 124:3221-3227.
23. Kruskal W.H., Wallis W.A. Use of ranks in one-criterion variance analysis. J Am Stat Assn 1952, 47:583-621.
24. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945, 1:80-83.
25. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958, 53:457-481.
26. Cox D.R. Regression models and life-tables. J Roy Statist Soc Ser B 1972, 34:187-220.
27. Lehman A. JMP for basic univariate and multivariate statistics: a step-by-step guide 2005, 123. SAS Press, Cary, NC.
28. Biancotto A., Feng X., Langweiler M., et al. Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects. Cytokine 2012, 60:438-446.
29. Krishnan V.V., Ravindran R., Wun T., et al. Multiplexed measurements of immunomodulator levels in peripheral blood of healthy subjects: Effects of analytical variables based on anticoagulants, age, and gender. Cytometry B Clin Cytom 2014, 86:426-435.
30. MacMillan M.L., DeFor T.E., Weisdorf D.J. The best endpoint for acute GVHD treatment trials. Blood 2010, 115:5412-5417.
31. Asplund S., Gramlich T.L. Chronic mucosal changes of the colon in graft-versus-host disease. Mod Pathol 1998, 11:513-515.
32. Poulsen S.S., Nexo E., Olsen P.S., et al. Immunohistochemical localization of epidermal growth factor in rat and man. Histochemistry 1986, 85:389-394.
33. Levine J.E., Huber E., Hammer S.T., et al. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood 2013, 122:1505-1509.
34. Leblond V., Salehian B.D., Borel C., et al. Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. Bone Marrow Transplant 1993, 11:299-305.
35. Matsuda Y., Hara J., Osugi Y., et al. Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. Bone Marrow Transplant 2001, 27:977-982.
36. Labrador J., Lopez-Anglada L., Perez-Lopez E., et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica 2013, 98:437-443.
37. Esch F.S., Shimasaki S., Mercado M., et al. Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol 1987, 1:849-855.
38. Nakamura T., Takio K., Eto Y., et al. Activin-binding protein from rat ovary is follistatin. Science 1990, 247:836-838.
39. de Kretser D.M., O'Hehir R.E., Hardy C.L., Hedger M.P. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol 2012, 359:101-106.
40. Gavino M.A., Wenemoser D., Wang I.E., Reddien P.W. Tissue absence initiates regeneration through Follistatin-mediated inhibition of Activin signaling. Elife 2013, 2:e00247.
41. Jones K.L., Mansell A., Patella S., et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci U S A 2007, 104:16239-16244.
42. Dohi T., Ejima C., Kato R., et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology 2005, 128:411-423.
43. Zhu J., Li Y., Lu A., et al. Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. Am J Pathol 2011, 179:915-930.
44. Enninga E.A., Nevala W.K., Creedon D.J., et al. Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period. Am J Reprod Immunol 2015, 73:251-262.
45. Phan C., McMahon A.W., Nelson R.C., et al. Activated lymphocytes promote endothelial cell detachment from matrix: a role for modulation of endothelial cell beta 1 integrin affinity. J Immunol 1999, 163:4557-4563.
46. Almici C., Skert C., Verardi R., et al. Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation 2014, 98:706-712.